Trial Testing AL101 in TNBC Doses First Patient

Trial Testing AL101 in TNBC Doses First Patient

286100

Trial Testing AL101 in TNBC Doses First Patient

The first participant has been dosed in the Phase 2 clinical trial TENACITY, which is evaluating Ayala Pharmaceuticals‘ investigational therapy AL101 as a treatment for Notch-activated recurrent or metastatic triple negative breast cancer (TNBC). AL101 is an investigational small molecule that inhibits Notch proteins. This family of cellular proteins plays important roles in governing cell growth during development. In some cancers, however, abnormal Notch signaling helps to facilitate cancer growth and survival. “We believe the…

You must be logged in to read/download the full post.